Chromogenic In Situ Hybridisation Test for Breast Cancer Patients with Equivocal IHC Results - a Study from Iran

Mehrazma, Mitra; Kalantari, Elham; Rezvani, Hamid; Bahar, Babak; Basi, Ali; Razavi, Seyed Mohsen; Rakhshani, Nasser

추천

검색

자료유형: 학술저널

저자정보: Mehrazma, Mitra (Oncopathology Research Center and Department of Pathology, Iran University of Medical sciences) Kalantari, Elham (Oncopathology Research Center, Iran University of Medical sciences) Rezvani, Hamid (Department of Oncology, Shahid Beheshti University of Medical Sciences) Bahar, Babak (Department of Oncology, Shariati Hospital Tehran University of Medical Sciences) Basi, Ali (Department of Oncology, GILDRC, Firoozgar Hospital, Iran University of Medical sciences) Razavi, Seyed Mohsen (Department of Oncology, GILDRC, Firoozgar Hospital, Iran University of Medical sciences) Rakhshani, Nasser (Department of Pathology, GILDRC, Firoozgar Hospital, Iran University of Medical sciences)

저널정보: 아시아태평양암예방학회 Asian Pacific journal of cancer prevention : APJCP Asian Pacific journal of cancer prevention : APJCP 제16권 제17호

발행연도: 2015.1

수록면: 7,695 - 7,700 (6page)

이용수

📌

연구주제

📖

연구배경

🔬

연구방법

🏆

연구결과

초록· 키워드

오류제보하기

Background: HER2/neu overexpression on cell membranes of breast cancer cells is due to HER2/neu gene amplification and it is important to identify potential candidates for anti HER2 therapy with trastuzumab. IHC, FISH and CISH are standard FDA approved assays currently used to determine HER2 status in routine practice. The aim of this study was to determine HER2 gene amplification, using the CISH method in breast carcinoma samples which had IHC +2 reactions. Materials and Methods: This study was conducted from 2008-2010 using 334 consecutive breast carcinoma samples referred from local laboratories to Mehr Hospital. CISH assays were performed for all cases, and IHC tests were also done for determining efficacy and accuracy of local labs. HER2 status in local IHC tests was compared with central IHC and CISH results. Results: Of 334 breast cancer patients, 16 were negative for HER2 IHC (0, +1), 201 cases were equivocal (+2), and 31 positive (+3). Of 334 referral cases, 88 were CISH positive (26.3%) and 246 were CISH negative (73.7%). Of 201 IHC +2 cases, HER2 gene amplification was observed in 42 cases (kappa: 0.42). A 29.9% concordance was found between local IHC and central IHC. Sensitivity and specificity of local IHC were 90% and 53.8%, respectively. Conclusions: Low accuracy of IHC results in local labs was associated with the following factors: using former FDA-approved criteria for HER2 interpretation, utilizing non-validated kits, and lack of any quality assurance program. Therefore, following the new 2014 ASCO/CAP guideline and comprehensive quality assurance should be implemented to ensure accuracy of HER2 testing.

#Breast cancer #CISH #IHC #HER-2/neu #Iran

참고문헌 (0)

참고문헌 신청

참고문헌이 DBpia에서 서비스 중이라면, [참고문헌 신청]을 통해 등록해보세요

함께 읽어보면 좋을 논문

논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!

이 논문의 저자 정보

Mehrazma, Mitra

소속기관 Oncopathology Research Center and Department of Pathology, Iran University of Medical sciences